Roivant Sciences Ltd. financials
Key figures from Roivant Sciences Ltd.'s filings with the U.S. Securities and Exchange Commission: the latest quarter against a year earlier, and the trend across recent quarters and fiscal years.
Latest quarter vs a year earlier
| Metric | Jun 2026 | Jun 2025 | Change |
|---|---|---|---|
| Revenue | $1M | $2M | -33.5% |
| Net income | -$190M | -$223M | +15.0% |
| Free cash flow | -$271M | -$208M | -30.0% |
| Gross margin | — | — | — |
| Operating margin | -25380.9% | -13130.0% | -12250.9 pts |
| Net margin | -13164.8% | -10292.9% | -2872.0 pts |
Quarterly trend
Fiscal years
| Fiscal year | Revenue | Net income | Net margin | Free cash flow | EPS (diluted) |
|---|---|---|---|---|---|
| FY Mar 2026 | $8M | -$300M | -3629.2% | -$759M | -$0.54 |
| FY Mar 2025 | $29M | -$172M | -592.0% | -$844M | -$0.24 |
| FY Mar 2023 | $32M | -$1.0B | -3200.2% | -$856M | -$1.42 |
| FY Mar 2022 | $55M | -$845M | -1528.9% | -$695M | -$1.26 |
| FY Mar 2021 | $24M | -$809M | -3400.9% | -$558M | — |
* Fiscal fourth quarter computed from the annual filing minus the three reported quarters. All figures from company filings with the SEC.